PAX3-FOXO1 fusion protein (PAX3-FOXO1)

PAX3-FOXO1 is a chimeric transcription factor resulting from the t(2;13)(q35;q14) chromosomal translocation, which is the hallmark of alveolar rhabdomyosarcoma (ARMS) [1.3.1, 1.4.1]. It combines the DNA-binding domain of PAX3 with the transactivation domain of FOXO1, creating a potent oncoprotein that drives a specific myogenic gene expression program [1.3.1, 1.4.2]. This fusion protein promotes cell proliferation, inhibits terminal muscle differentiation, and enhances survival and metastasis [1.2.2, 1.3.5]. While it is a highly specific and validated therapeutic target, its nature as a transcription factor has made it historically difficult to target directly with small molecules [1.1.1, 1.2.1]. Current research focuses on indirect targeting through epigenetic modifiers like HDAC and BET inhibitors, which modulate the protein's expression or its interaction with chromatin [1.2.1, 1.2.3]. Emerging technologies such as Proteolysis Targeting Chimeras (PROTACs) are also being developed to induce the targeted degradation of the PAX3-FOXO1 protein [1.3.4]. Additionally, targeting downstream effectors like MET, ALK, and IGF1R provides an alternative strategy to mitigate the oncogenic signaling initiated by the fusion protein [1.3.1]. Because its expression is restricted to tumor cells, PAX3-FOXO1 represents an ideal target for precision medicine in pediatric oncology [1.3.1, 1.3.2].

Other names

PAX3-FKHRt(2;13)(q35;q14) fusion proteinPAX3-FOXO1A fusion proteinPAX3::FOXO1

Direct inhibition of transcriptional activity; Epigenetic modulation via HDAC or BET inhibition to suppress fusion protein expression or activity; Targeted protein degradation via PROTACs; Inhibition of downstream signaling effectors (e.g., MET, ALK, IGF1R) [1.2.1, 1.3.1, 1.3.4].